



International Journal of

Innovative Drug Discovery

www.ijidd.com

e ISSN 2249 - 7609
Print ISSN 2249 - 7617

PRODRUG DESIGN AND APPLICATION: ENHANCING DRUG PHARMACOKINETICS

Asha Jyothi P*, Soundharya P, Sravanthi D, Vasavi P, Vijay Kushal B

KLR Pharmacy College, Paloncha, Telangana, India.

ABSTRACT

Prodrugs are drugs which are inactive and whose pharmacological effects are enhanced to improve the pharmacokinetics of drugs i.e., their solubility, stability, absorption and target delivery. They are converted into active drug by enzymatic work or chemical transformation in the body overcoming such difficulties as low bioavailability and selective targeting. Prodrugs are categorized according to the conversion location (carrier-linked and bioprecursors) and targets of therapeutic agents (site-specific and transport-targeted). The specific delivery of the drug to the target site of action can be observed under different activation procedures such as enzymatic and different chemical processes. Prodrugs have great potential in personalized medicine, enhancing efficacy and safety of drugs, since the therapies can be directly personalized in response to specific genetic and metabolic characteristics of individuals. Moreover, nanotechnology, enzyme-target, and AI are also advancing in the development of prodrugs, making them more precise. This review examines the mechanisms, uses, and future trends in the design of prodrugs and how those can reshape the development of drugs and enhance clinical outcomes.

KEY WORDS: Prodrugs, Pharmacokinetics, Targeted Drug Delivery, Personalized Medicine, Nanocarriers.

INTRODUCTION

Definition of Prodrugs

Prodrugs are pharmacologically inactive compounds that on administration are converted into their active drugs in an enzymatic or chemical reaction. This is a change that takes place once the prodrug is taken to the body, usually through enzymatic action in the liver or other body tissues and leads to the activation of the drug. Prodrugs are geared towards enhancing the delivery of absorption or distribution of the active drug, which otherwise may not be ideal to be used therapeutically because of such factors as low solubility, stability, or bioavailability. [1, 2]

Justification of Prodrug Strategies

The prodrug strategies are also commonly motivated by the need to circumvent the drug limitations that come with the physicochemical properties of a drug. These may be poor solubility, instability of the gastrointestinal tract, or the inability to pass biological

barriers such as the blood-brain barrier. [3, 4] Prodrugs can be used to increase oral bioavailability, tissue targeting of a drug, and reduce side effects through the change of chemical structure of a drug. Furthermore, the prodrug strategies may be used to prolong the action of the drug and enhance the compliance of the patients by decreasing the drug dosing. [1, 3, 5].

Goals of Enhancing Pharmacokinetic Monitoring

Prodrug design Pharmacokinetic enhancement is a method to maximize the absorption, distribution, metabolism, and excretion (ADME) characteristics of a drug. The ultimate objective is to enhance the bioavailability of the medicine that is to get the drug to the location of action at therapeutic levels. Prodrugs have been designed to increase the dissolution ability of a drug, prevent the degradation of the active compound, and achieve easier delivery to the target tissues. [6, 7] In addition, prodrug approaches may aid in the management of the release profile of the drug, which guarantees a more

Corresponding Author: - **Asha Jyothi P** Email: - pattaashajyothi8@gmail.com

stable effect of the therapeutic effect but with fewer toxic side effects that could appear. Finally, the pharmacokinetic enhancement aims at enhancing efficacy and safety profile of the drug, and thus to augment overall therapeutic value. [8, 9].

Classification of Prodrugs

Based on Site of Conversion

Carrier-Linked Prodrugs

Carrier-linked prodrugs Prodrug Carrier-linked prodrugs are a kind of prodrug in which the active drug is chemically bound to a carrier molecule, which assists in enhancing the solubility, stability, or bio-permeability of the active drug. The carrier is typically a hydrophilic or lipophilic molecule, which is attached to the drug via a cleavable bond. When the carrier molecule is absorbed into the body it is enzymatically split up and the active drug is released where it is required. [8, 10] This plan augments the pharmacokinetic features of the drug and may augment oral bioavailability or targeted delivery. Carrier-linked prodrugs are usually applied in cases where the drug itself is not very permeable or soluble. [8, 11]

Bio precursors

Bio precursors are prodrugs that need to undergo metabolic activation in the body before they produce the active drug. Bio precursors as opposed to carrier-linked prodrugs do not have a carrier molecule. Rather, the prodrug is a precursor itself which is enzymatically converted in the body to liberate the active pharmaceutical ingredient. This form of prodrug is usually employed to enhance pharmacokinetics of a drug by increasing its absorption or stability in vivo prior to its reaching its target site. After being metabolized, the active form of the drug may have its therapeutic action. Cases of drugs which are poorly absorbed or unstable in their active form are often bio prescribed. [7, 12]

Based on Therapeutic Target

Site-Specific Prodrugs

The site-specific prodrugs will be focused on releasing the active drug at a specific location in the body to increase the therapeutic effect and reduce side effects. This is done through the delivery to the target tissues or organs, including tumors or inflamed tissues, to which the prodrug can be activated. Targeting moieties or delivery systems which are known by particular receptors or enzymes in the target site are often used in site-specific prodrugs. This method enables the high drug concentration on the site of action and a low level of exposure to the system in general, which enhances efficacy and safety, especially in therapies such as cancer or inflammatory diseases. [13, 14]

Targeted Prodrugs of Transport.

Transport-targeted prodrugs are prodrugs that improve the delivery of a drug to a limited number of cells or tissues by exploiting transport systems, including active transporters or carrier proteins, found on the cell membrane. The prodrug is altered chemically so that it is accepted by these transport systems, in which case it is efficiently absorbed by the target cells. After entering the cells, the prodrug is activated and releases the active drug. The technique is particularly beneficial in the overall delivery of drugs to cells that bear a particular transporter like in the brain, liver, or tumors. Transport-targeted prodrugs provide a method of enhancing drug delivery to cells which are difficult to reach and making the treatment more effective and off-target effects minimized.[1, 15].

Mechanisms of Prodrug Activation

Enzymatic Activation

Enzymatic conversion is also a widely used system of prodrug conversion, where certain enzymes are used to improve the conversion of the prodrug to an active form. Some of the most common enzymes that are involved in this process are esterases and phosphatases. Esterases catalyze the hydrolysis of ester bonds and the active drug within a carrier molecule is liberated and phosphatases catalyze the removal of phosphate groups off prodrugs activating them. Such an enzymatic transformation mainly takes place in the liver and may also be found in other tissues which possess these enzymes. [16]The prodrugs can be developed to make the active drug release upon the presence of the specific enzyme activity where and when it is required, maximizing the desired therapeutic effects and minimizing the systemic side effects. [1, 8]

Chemical Activation

Non-enzymatic activities in the chemistry activation of prodrugs include hydrolysis or oxidation to modify the prodrug into an active form. Hydrolysis usually entails the dissolution of the ester or amide bonds in the prodrug by the water, which liberates the active drug. [8,10]On the other hand, oxidation is the addition of oxygen or deprivation of electrons in the prodrug and converting it into an active pharmaceutical compound. Such chemical reactions may take place either in the gastrointestinal tract, liver or any other tissue and in most cases, it depends on the pH or the redox condition that results in the conversion. Prodrugs which rely on non-enzymatic activation via stable processes are also useful with chemical activation, and can be utilized when it is not necessary to control the activity of an enzyme.[11, 17]

Target Site-Specific Enzyme Conversions

Target site-specific enzymatic conversions are prodrug approaches that are planned to stimulate the drug at its exact site of action in the body. This is done through

the designing of prodrugs that get cleaved by the enzymes that are only expressed or highly active in the target site. As an example, prodrugs can be designed in such a way that they are activated by enzymes in tumor tissues, inflamed regions, or individual organs such as the liver. [18, 19] This local conversion enables conversion of drugs to be localized so that therapeutic effects at the target site are maximized whilst avoiding exposure and toxicity to normal tissues. Prodrug approaches are especially useful in specific cancer therapies, inflammatory disorders, and other diseases that require localized therapy as the most effective approach. [8, 18].

Pharmacokinetic Improvements via Prodrug Design Increased Aqueous Solubility

The low solubility of most drugs in water is one of the greatest problems in drug formulation and may restrict the bioavailability of drugs. Prodrug strategies can also optimize aqueous solubility of the drug by altering its chemical structure. Prodrug can be more readily dissolved in the gastrointestinal fluids by the addition of hydrophilic molecules or modification of the shape of the drug to ensure that adequate amount of drug is present to be absorbed. After the prodrug is absorbed into systemic circulation it can be broken down into its active state and this is a great benefit of delivering drugs that are not very soluble. This method is especially applicable to hydrophobic drugs which are not easily taken by mouth.[4,10]

Improved Permeability and Absorption of Membranes

The prodrugs can be also designed to enhance the permeability of the membranes so that drugs can get into the target location more easily by penetrating the cellular membranes.[7,20] This is more important with drugs that require an ability to penetrate biological barriers, e.g., the blood-brain barrier or gastrointestinal epithelium. Prodrug can be used to increase absorption across the intestinal wall by altering the drug to increase its lipophilic properties or decrease its polarity resulting in increased plasma concentrations of the active drug. It is common in compounds that do not absorb well, which avoids wastage and results in the drug being used therapeutically in the blood. [21, 22]

Prolonged Half-Life

Prodrugs may be made to have a longer half-life in the body and this helps in prolonging therapeutic drug levels in the body. This is normally done through altering the drug to have a slower metabolism or lower rate of elimination. [23, 24] Long half-life prodrugs may be especially beneficial in chronic disease, where there would be a need to have long-term, consistent drug delivery. Prodrug strategies can enhance patient compliance by limiting the number of doses required, as well as reduce intermittent effects of drug concentration,

which causes more consistent therapeutic responses. [7, 25]

Decreased First-Pass Metabolism

First-pass metabolism is a metabolism process where a drug is metabolized by the liver prior to absorption into the systemic circulation and this may decrease its bioavailability. In order to avoid or minimize first-pass metabolism, the prodrug is commonly formulated with different properties to avoid initial metabolism or reduce the effect of first-pass metabolism through changing the structure of the drug to enable its absorption into the bloodstream without initial breakdown in the liver. After absorption, the prodrug would be converted into its active form, and it would result in increased exposure to the drug. This advantage is especially relevant to drugs of low oral bioavailability because of a high level of metabolism in the liver, so a greater quantity of the drug reaches the site of action. [5, 26]

Enhanced Bioavailability

Increasing bioavailability is among the main aspects of prodrug design. Prodrug can enhance first pass metabolism by increasing the solubility, permeability, half-life and can reduce the first pass metabolism to improve the amount of drug that is available in the bloodstream and finally to reach the target site. This is because in case of increased bioavailability, the drug can be able to perform the therapeutic effects that it must perform much more efficiently, at the same doses and at lower side effects [10, 27]. It is especially relevant to those drugs which are ill-absorbed or swiftly delivered out of the body and provide an opportunity to enhance the drug and decrease the dosing rate. The improved bioavailability eventually results in improved patient outcomes and efficacious treatments. [10, 22].

Prodrug Design Considerations

Modification of the functional groups via the functional group selection

In designing prodrugs, the choice of functional group to be modified is extremely important to the provision of desired pharmacokinetic properties. The functional group should be selected on the basis of its capacity to enhance the solubility of the drug, its permeability or stability as well as the effective transformation of the prodrug to the active form. Usually, functional groups such as esters, amides, phosphates, and carbamates are employed in designing prodrugs; and the group can be broken down by enzymes or by chemical reactions to free the active drug. The functional group has to be stable in order to avoid premature activation and yet be labile to facilitate effective conversion when the prodrug has reached its target site. The selection of functional groups should be done in a proper manner in

order to maximize the therapeutic effect of the drug and at the same time reduce the side effects. [7, 28]

Stability and Timing of Activation

The prodrug stability and the time when it is activated is a vital aspect to be considered in design. Prodrugs should be resistant enough to endure conditions within the gastrointestinal tract, circulatory system, or other biological conditions until the activation takes place. Nevertheless, they should also be vulnerable to be activated when and where required in the body. [1, 29] This necessitates a precise structuring of the chemical form of the prodrug, in order to make sure that it is only activated once at the target site or after a series of enzymatic or chemical reactions have occurred. To ensure optimal therapeutic effects at the lowest risk of toxicity or off-target effects, it is crucial to have the appropriate equilibrium between stability and timely activation. [30–32]

Toxicity and Safety of Promoieties

The chemical entities that are bound to a drug in a prodrug system, which are referred to as promoieties, are to increase the pharmacokinetic characteristics of the drug that is being used and thus their toxicity and safety profile should be critically considered. Although promoieties can have a crucial positive effect on solubility, absorption, and targeting, they must not be a threat of adverse aftereffects when released or metabolized. [1, 9, 33] The toxicity studies should also examine the active drug and the promoiety so that they do not lead to adverse reactions at therapeutic doses. Also, it is important to monitor the possibility of the accumulation of the promoiety in the tissues or its interaction with other biological systems. The safety of a prodrug is determined by the active drug, the chemical structure of the promoiety, and its capability to safely be metabolized or excreted via the body. [3]

Enzymatic Availability and Variability

Enzymatic variability and availability are also essential factors to be put into consideration when developing enzyme-dependent prodrugs. The conversion of the prodrug is conditional on the presence of certain enzymes in the target tissue or organ and changes in the expression of these enzymes may have an influence on drug efficacy. Genetic variations, age, disease condition and environmental conditions are all known to produce variations in enzyme activity. Thus, it is crucial to know the enzymatic environment of the target site to be able to design prodrugs that can be activated with a high degree of reliability. Moreover, differences in the availability of enzymes also have to be considered to assure that the prodrug will be activated at the correct time and location to bring about consistent therapeutic effects in different groups of patients.

Prodrug Applications in Various Drug Classes

Antiviral exercise (e.g., Tenofovir Disoproxil)

Poorly bioavailable antiviral agents or agents that may need targeting have also been developed effectively as prodrug that improves pharmacokinetic properties of antiviral agents. One of these prodrugs is the tenofovir disoproxil that enhances the bioavailability of the active constituent of tenofovir which has poor bioavailability and low tissue penetration. Tenofovir is more lipophilicized into disoproxil ester and is readily absorbed and disseminated in a body. The disoproxil group is injected inside the body, where esterases can cleave the group to release the active drug, which in turn, can exert its antiviral effect on HIV and hepatitis B, which can be regarded as an effective strategy in antiviral drug design because the drug delivery can be improved, and the drug efficacy can be enhanced and the frequency of the dosage can be decreased. [34]

Anticancer Agents

Capecitabine is a prodrug which finds its application in the management of cancer particularly the breast cancer, colon cancer and gastric cancer. Capecitabine as a prodrug is intended to augment the pharmacokinetics of the active metabolite, 5-fluorouracil (5-FU) as it is widely used in chemotherapy but has a restriction on its toxicity and therapeutic index. The activation of capecitabine into 5-FU is selectively done with highly expressed tumor tissue enzymes that provide particular delivery of the active drug. This non-random activation will minimize the systemic toxicity and maximize the clinical effect of the drug on malignant cells, and the adverse effect on normal and healthy tissues is less severe. This is a prodrug approach that will make the treatment of anticancer more correct and result in more effective and less toxic treatments. [35, 36]

NSAIDs

Other drugs that involve the use of prodrugs to produce effective drugs include nonsteroidal anti-inflammatory drugs (NSAIDs) whereby a prodrug such as Nabumetone is a prodrug of 6-methoxy-2-naphthylacetic acid. The prodrug type is easily absorbed in the gastrointestinal tract due to their being more soluble in the gastrointestinal tract compared to that of the active form. On absorption, Nabumetone is metabolized in the liver to active drug that possesses anti-inflammatory, analgesic and antipyretic effects. [37] The use of prodrugs like Nabumetone can be used to increase the level of patient compliance because it will assist in reducing the gastrointestinal irritation and adverse effects common with conventional NSAIDs. In addition, prodrug strategies in NSAID can be designed in such a way that it selects certain tissues and enhances the therapeutic profile and reduces adverse effect. [1]

Cardiovascular Drugs

Prodrug applications in the formation of cardiovascular drugs are also not an exception, and they help to enhance the bioavailability of active substances and their targeting. Heart and blood drugs (hypertension, heart failure, angina, etc.) also have a high likelihood of having many problems including low solubility or short half-life. Under such designing of prodrugs that can be converted to their active forms in some tissues the drugs can be delivered much better and therefore bring better therapeutic effects. Prodrug method in cardiovascular therapy typically involves trying to achieve stability of the drug, reduction of first pass metabolism, and absorption that will result in a better control of heart rate, blood pressure as well as vascular tone in the patient that will translate to better patient outcome in heart diseases. [1, 38, 39]

Blood-Brain Barrier CNS-Active Drugs.

The obstacle of blood-brain barrier (BBB) to the action of therapeutic agents not specific to the brain is one of the biggest barriers to drug development that have CNS-activity. The prodrug approaches also come in the most convenient way of avoiding this barrier by modifying drugs to enable them to become lipophilic and able to cross the BBB. After the prodrug enters the brain it is then transformed into the active form and then it can carry out its therapeutic action. An example would be to use some antipsychotic, analgesic and anticonvulsant medications that are designed as prodrugs to increase the ability of the drug to enter the BBB. It is also required in the treatment of neurological disorders such as the Alzheimer disease, Parkinson disease, epilepsy, depression where the drug administered onto the brain is the most crucial element in treating this disease. The prodrug design of the CNS-active drugs gives the possibility of the drug delivery to be more effectual, reduced side effects, and better treatment of the neurological disorders. [40, 41]

Regulatory and Developmental Challenges

Prodrug Approval Regulatory Guidelines.

The approval of prodrugs has been outlined with great guidelines by regulatory authorities, such as the U.S. FDA, EMA, as well as ICH. Such directives are aimed at making sure that prodrugs fulfill the required safety, efficacy and quality requirements before they are put to market. The drugs are tested on their stability in chemistry, pharmacokinetics, and efficacy of the prodrug conversion process to the active drug form. The regulatory agencies demand detailed research that shows that the prodrug is always transformed to its active form under physiological conditions. Pharmacokinetic profiles, including bioavailability, distribution, metabolism, and excretion, should also be evaluated properly, and the information about any possible drug-drug interactions

should be present. Another battle that would lead to successful approval is showing that the benefits of the prodrug surpass any risk that may be posed as a result of the conversion process. [7, 11]

Toxicological Evaluation

Toxicological assessment is an important part of the prodrug development, because the inactive compound has to be proven to be harmless to use by humans. Preclinical experiments aim at determining the pharmacokinetic potential of the prodrug and its metabolites including toxicity, especially that caused by the prodrug or the products that are obtained following conversion.[42, 43] Such studies normally comprise of acute, subacute and chronic toxicity, genotoxicity and carcinogenicity testing. Additionally, the effects of the prodrug on other body organs, like liver and kidneys are also monitored. Safety pharmacology evaluations should also be done on the prodrug to determine whether the drug has any adverse effect on the cardiovascular, respiratory system or central nervous system. This is a toxicological information that guides the approval of new regulations and also gives safety assurance to the participants of the clinical trials. [42, 44]

In Vivo Conversion Rates Prediction.

An important and complicated procedure in prodrug development is the prediction of in vivo conversion rates. The rate of conversion of a prodrug to an active form is determined by a number of factors which include enzymatic activity, level of pH and tissue specifics. [45, 46] In vitro experiments such as enzyme assays and tissue homogenate studies give information on the metabolism of the prodrug. Nevertheless, modeling is necessary to predict the precise conversion rate in humans, typically through the in-silico approach or physiologically-based pharmacokinetic (PBPK) models which are models that model drug absorption, distribution, metabolism, and excretion. [47, 48] These models may aid in estimating the behaviour of the prodrug in different tissues, and they will behave in different physiological conditions. It is important to precisely predict the conversion rates to ascertain that the prodrug can be effective and safe in the clinical settings. [47, 49]

Complexities of Clinical Trials Designs

The design of clinical trials of prodrugs has special difficulties in contrast to the classical drug development. Since prodrugs are inactive substances, which need to be metabolically transformed to produce their therapeutic action, it is important to take into consideration the pharmacokinetic characteristics of both the prodrug and the active version.[7,11,50] The trial design should be based on the time-span needed to ensure that the conversion in question takes place and the rate at

which various individuals convert. Frequently, dose escalation studies are required to find the most suitable dosing regimen, such that bioavailability and therapeutic effect are adequate, but toxicity does not become excessive.[3,51] Also, biomarkers can be needed to track the conversion of the prodrug in real-time. Moreover, the clinical trials should be modeled to analyze both the prodrug and the active metabolites of the drug to obtain a complete picture of the efficacy and safety profile of the drug. Thus, proper planning and dynamic trial design is very important to defeat these complexities and make sure that prodrugs are properly assessed regarding their clinical potential.[8, 11, 52]

8. Emerging Trends and Future Prospects

Personalized Medicine: Prodrugs

Prodrugs have great potential in personalized medicine because they improve drug delivery and maximize the therapies of individual patients. Personalized medicine is aimed at customizing the treatment depending on the genetic profile of a patient, his/her lifestyle, and peculiarities of a disease. Prodrugs are also able to be developed so as to target the distinct metabolic phenotypes of individuals, so that they will only be activated in the absence of particular enzymes or conditions, including pH or tissue specific features[53,54]. The method reduces the possibility of any adverse effects and maximizes therapeutic efficacy due to the delivery of the active drug in the right time and place. Also, an individualised prodrug approach may be used to enhance the bioavailability of poorly soluble or absorbed drugs thereby offering a more tailored and effective therapy to patients. With the ever-growing development of genomic data and the discovery of biomarkers, it is possible to incorporate prodrugs into precision medicine to deliver more effective and personalized treatments. [55, 56]

Prodrug-Nanocarrier Hybrids

Prodrug- nanocarrier hybrids are a novel category of drug delivery that includes the advantages of both prodrugs and nanotechnology. Nanoparticles, dendrimers, and liposomes are some of the nanocarriers that are used to deliver drugs, enhance their bioavailability, stability, and targeting. These hybrids can have other benefits when used together with prodrugs e.g. increased localization to target sites and controlled release [55, 57]. The prodrug molecule would help in keeping the drug inactive until it gets to the intended site, whereas the nanocarrier would help in delivering the drug in a controlled and sustained manner over time. This method is synergistic especially when it is applied to hard-to-reach regions like tumors, brain tissue or sites of infection. [1, 55] Moreover, nanocarrier size and surface characteristics can be localized to enhance cellular

absorption, decrease off-target, and increase the index of therapeutics. Hybrid prodrug-nanocarrier hybrids, therefore, have potential in various therapeutic treatments such as cancer therapy, gene therapy and managing chronic diseases, in which the aspect of targeted drug delivery is crucial.[58, 59]

Gene-Activated and Enzyme-Targeted Prodrugs

Enzyme-targeted and gene-activated prodrug is a new approach of targeted drug delivery. Enzyme-targeted prodrugs are prepared such that they can only be released by certain enzymes which are expressed in excess in disease tissue or cells like in a tumor or an infected tissue.[60] The prodrugs are inactive until met with the target enzyme so that the therapeutic agent is released only in the region of need which reduces systemic toxicity and increases the therapeutic effects of the drug. On the other hand, gene-activated prodrug depends on the presence of a certain gene in the body to activate the prodrug.[1,8] This methodology is specifically applicable in cancer therapy when tumor cells can over express specific genes that can activate the prodrug. These two approaches exploit the disease-specific processes to provide localized drug activation, which promises as a promising treatment in more selective and less toxic therapies.[19, 61]

Role of AI in Prodrug Design

The role of Artificial Intelligence (AI) is becoming more prominent in the creation and development of prodrugs with some never-before-seen opportunities and possibilities to predict drug efficacy, optimize structure, and speed up the discovery of drugs. [62, 63] The AI algorithms, machine learning and deep learning, could be used to analyze large datasets, including chemical libraries, biological data, and clinical trial outcomes to help determine the desired properties of potential prodrug candidates. [62, 64] Using AI models, researchers are able to forecast the pharmacokinetics, toxicity and conversion rates of prodrugs prior to experimental testing and thus time and resources saved. The identification of potential enzyme targets upon prodrug activation, simulation of the prodrug metabolic pathway, and optimization of the structuring of the prodrug to be more bioavailable and less side-effect improvement can be achieved with the use of AI as well. [7, 8, 65] Also, AI-based technologies can help with the design of personalized prodrugs, including patient-specific information, including genetic variations, and these factors can affect prodrug activation and response. Altogether, AI helps to revolutionize the design of prodrugs, making it more accurate, minimizing trial and error, and helping to develop more effective and targeted treatments. [8, 66, 67]

Table 1: Classification of Prodrugs


Classification	Type	Description
Site of Conversion	Carrier-Linked Prodrugs	Drug is chemically bonded to a carrier molecule to improve solubility or permeability.
Bioprecursors	Prodrug is metabolized into the active drug without a carrier.	
Therapeutic Target	Site-Specific Prodrugs	Activated at specific sites in the body (e.g.,
Transport-Targeted Prodrugs	Utilizes transport mechanisms for targeted delivery to specific cells.	

Table 2: Mechanisms of Prodrug Activation.

Activation Mechanism	Process Description
Enzymatic Activation	Conversion by specific enzymes like
Chemical Activation	Non-enzymatic processes, such as hydrolysis or oxidation.
Target Site-Specific Enzymatic Conversions	Activation by enzymes uniquely expressed in target tissues (e.g.,

Table 3: Pharmacokinetic Improvements via Prodrug Design

Pharmacokinetic Improvement	Description
Improved Aqueous Solubility	Prodrugs designed to enhance solubility in water for better absorption.
Enhanced Membrane Permeability	Modifications to improve the ability of the drug to cross cellular membranes.
Prolonged Half-Life	Slows down drug metabolism for sustained therapeutic effects.
Reduced First-Pass Metabolism	Avoids early liver breakdown, increasing bioavailability.
Enhanced Bioavailability	Optimizes the overall absorption and delivery of the drug.



CONCLUSION

Prodrug design is a radical way of improving drug development that improves pharmacokinetic performance to address drug development issues including low solubility, biomolecular accessibility, and local delivery to the tissue.

Prodrugs can be used to enhance the absorption, stability and controlled release of drugs resulting in more efficient and effective therapies as a result of strategic modification. Designing prodrugs which can be activated at a particular location in the body makes it possible to deliver drugs in

specific sites and this reduces their side effects and enhances their therapeutic effects, particularly where such drugs are used as cancer, viruses, and chronic diseases. In addition, the introduction of a combination of modern technologies, including nanocarriers, activation of enzymes, and artificial intelligence into the construction of prodrugs can have a tremendous potential on the personalized approach to medicine, where the treatment is designed to address the needs of a particular patient. In spite of these

achievements, there are still difficulties, such as the requirement of accurate clinical trial designs, proper forecast of the conversion rates, and comprehensive regulatory assessment. With the evolution of the field, innovative approach to the prodrug strategies is still continuing and is expected to transform the manner in which we approach the treatment of patients with drugs, offering improved, safer and more personalized treatment to patients across the globe.

REFERENCES

1. Tu, Y., Jiang, H., Gao, J., Zhao, H., Mou, J., & Gong, J. Strategies for the development of stimuli-responsive small molecule prodrugs for cancer treatment. *Frontiers in Pharmacology*, 15, 2024.
2. Buya, A. B., Makoni, P. A., Nkanga, C. I., Mwila, C., Bapolisi, A. M., Witika, B. A., et al. Application of lipid-based nanocarriers for antitubercular drug delivery: A review. *Pharmaceutics*, 13(12), 2021, 2041.
3. Karbasi, A. B., Barfuss, J. D., Morgan, T. C., Collins, D., Costenbader, D. A., Dennis, D. G., et al. Sol-moiety: Discovery of a water-soluble prodrug technology for enhanced oral bioavailability of insoluble therapeutics. *Nature Communications*, 15, 2024.
4. Li, Y., Sun, J., Liu, X., Wang, W., Ma, Z., Jiang, Q., et al. Natural amino acid-bearing carbamate prodrugs of daidzein increase water solubility and improve phase II metabolic stability for enhanced oral bioavailability. *Journal of Agricultural and Food Chemistry*, 72, 2024, 8618-8631.
5. Wang, X., Zhang, C., Han, N., Luo, J., Zhang, S., Wang, C., et al. Triglyceride-mimetic prodrugs of scutellarin enhance oral bioavailability by promoting intestinal lymphatic transport and avoiding first-pass metabolism. *Drug Delivery*, 28, 2021, 1664-1672.
6. Bhalani, D. V., Nutan, B., Kumar, A., & Singh Chandel, A. K. Bioavailability enhancement techniques for poorly aqueous soluble drugs and therapeutics. *Biomedicines*, 10(9), 2022, 2055.
7. Subbaiah, M. A. M., Rautio, J., & Meanwell, N. A. Prodrugs as empowering tools in drug discovery and development: Recent strategic applications of drug delivery solutions to mitigate challenges associated with lead compounds and drug candidates. *Chemical Society Reviews*, 53, 2024, 2099-2210.
8. Kurian, R., & Wang, H. Prodrugs in oncology: Bioactivation and impact on therapeutic efficacy and toxicity. *International Journal of Molecular Sciences*, 26(3), 2025, 988.
9. He, X., Li, J., Liang, X., Mao, W., Deng, X., Qin, M., et al. An all-in-one tetrazine reagent for cysteine-selective labeling and bioorthogonal activable prodrug construction. *Nature Communications*, 15, 2024.
10. Tantra, T., Thareja, S., Singh, Y., Kulkarni, S., Kumar, P., & Patekar, R. Phosphate prodrugs: An approach to improve the bioavailability of clinically approved drugs. *Current Medicinal Chemistry*, 31, 2024, 336-357.
11. Bargakshatriya, R., & Pramanik, S. K. Stimuli-responsive prodrug chemistries for cancer therapy. *ChemBioChem*, 24, 2023.
12. Singh, G., Majeed, A., Singh, R., George, N., Singh, G., Gupta, S., et al. CuAAC ensembled 1,2,3-triazole linked nanogels for targeted drug delivery: A review. *RSC Advances*, 13, 2023, 2912-2936.
13. Ma, S., Tang, B., Kim, J. H., Xue, J., Chen, G., Chen, W., et al. Cancer cell-specific fluorescent prodrug delivery platforms. *Advanced Science*, 10, 2023.
14. Kotla, N. G., Singh, R., Baby, B. V., Rasala, S., Rasool, J., Hynes, S. O., et al. Inflammation-specific targeted carriers for local drug delivery to inflammatory bowel disease. *Biomaterials*, 281, 2022, 121364.
15. Jiang, Y., Chen, H., Lin, T., Zhang, C., Shen, J., Chen, J., et al. Ultrasound-activated prodrug-loaded liposome for efficient cancer targeting therapy without chemotherapy-induced side effects. *Journal of Pharmaceutical Sciences*, 112, 2023, 1234-1245.
16. Lu, N., Han, X., Wang, Y., Zha, Z., Ge, Z., Xi, L. Acid-responsive endosomolytic polymeric nanoparticles with amplification of intracellular oxidative stress for prodrug delivery and activation. *Biomaterials Science*, 9, 2021, 4613-4629.
17. Nosrati, Z., Chen, Y. A., Bergamo, M., Rodríguez-Rodríguez, C., Chan, J., Shojania, K., et al. Prodrug nanomedicine for synovium targeted therapy of inflammatory arthritis: Insights from animal model and human synovial joint fluid. *Advanced Healthcare Materials*, 13, 2024.
18. Quintana, J. M., Kang, M., Hu, H., Ng, T. S. C., Wojtkiewicz, G. R., Scott, E., et al. Extended pharmacokinetics improve site-specific prodrug activation using radiation. *ACS Central Science*, 10, 2024, 1371-1382.
19. Sitovs, A., & Mohylyuk, V. Ex vivo permeability study of poorly soluble drugs across gastrointestinal membranes: Acceptor compartment media composition. *Drug Discovery Today*, 29, 2024, 104214.

20. Montaser, A. B., Lehtonen, M., Auriola, S., Järvinen, J., Huttunen, K. M., Löffler, S., et al. L-Type amino acid transporter 1 enables the efficient brain delivery of small-sized prodrug across the blood-brain barrier and into human and mouse brain parenchymal cells. *ACS Chemical Neuroscience*, 11, 2020, 4301-4315.
21. Gote, V., Ansong, M., & Pal, D. Prodrugs and nanomicelles to overcome ocular barriers for drug penetration. *Expert Opinion on Drug Metabolism & Toxicology*, 16, 2020, 885-906.
22. Meiers, J., Rox, K., & Titz, A. Lectin-targeted prodrugs activated by *Pseudomonas aeruginosa* for self-destructive antibiotic release. *Journal of Medicinal Chemistry*, 65, 2022, 13988-14014.
23. Matošević, A., & Bosak, A. Carbamate group as structural motif in drugs: A review of carbamate derivatives used as therapeutic agents. *Archives of Industrial Hygiene and Toxicology*, 71, 2020, 285-299.
24. Nayan, M. U., Panja, S., Sultana, A., Zaman, L. A., Vora, L. K., Sillman, B., et al. Polymer delivery systems for long-acting antiretroviral drugs. *Pharmaceutics*, 16, 2024, 183.
25. Islam, N., Irfan, M., Hussain, T., Mushtaq, M., Khan, I. U., Yousaf, A. M., et al. Piperine phytosomes for bioavailability enhancement of domperidone. *Journal of Liposome Research*, 32, 2021, 172-180.
26. Zhang, L., Zhu, L., Tang, L., Xie, J., Gao, Y., Yu, C., et al. Glutathione-responsive nanoparticles of camptothecin prodrug for cancer therapy. *Advanced Science*, 10, 2022, 2205246.
27. Alvani, A., & Shayanfar, A. Solution stability of pharmaceutical cocrystals. *Crystal Growth & Design*, 22, 2022, 6323-6337.
28. Zhang, X., Jia, S., Yu, P., Cao, C., Zhang, X., Shi, X., et al. Dual-prodrug cascade activation for chemo/chemodynamic mutually beneficial combination cancer therapy. *Biomaterials Science*, 11, 2023, 1066-1074.
29. Fu, Q., Sun, P., Shen, S., Bai, Y., Liu, Z., Gu, Z., et al. Bioorthogonal chemistry for prodrug activation in vivo. *Chemical Society Reviews*, 52, 2023, 7737-7772.
31. Southwell, J. W., Thomas, G. H., Duhme-Klair, A., Gutenthaler, S. M., Wilson, K. S., Herman, R., et al. Siderophore-linked ruthenium catalysts for targeted allyl ester prodrug activation within bacterial cells. *Chemistry – A European Journal*, 29, 2022.
32. Zhang, Y., Pei, Q., Xie, Z., & Yue, Y. Binary dimeric prodrug nanoparticles for self-boosted drug release and synergistic chemo-photodynamic therapy. *Journal of Materials Chemistry B*, 10, 2022, 880-886.
33. Li, M., Dong, Y., Wang, Z., Zhao, Y., Dai, Y., Zhang, B. Engineering hypoxia-responsive 6-aminonicotinamide prodrugs for on-demand NADPH depletion and redox manipulation. *Journal of Materials Chemistry B*, 12, 2024, 8067-8075.
34. Li, B., Liu, Q., Liu, X., Liu, D., Duan, M., Liu, Z., et al. Efficacy and safety of tenofovir disoproxil fumarate and tenofovir alafenamide fumarate in preventing HBV vertical transmission of high maternal viral load. *Hepatology International*, 15, 2021, 1103-1108.
35. Al-Jaber, H., Biswas, K. H., & Al-Mansoori, L. Advancing targeted therapy for colorectal cancer: Harnessing ligand-directed enzyme prodrug therapy for highly specific interventions. *Frontiers in Oncology*, 15, 2025.
36. Alzahrani, S., Al Doghaither, H., Al Ghafari, A., & Pushparaj, P. 5-Fluorouracil and capecitabine therapies for the treatment of colorectal cancer (Review). *Oncology Reports*, 50, 2023.
37. Czub, M. P., Venkataramany, B. S., Cooper, D. R., Shabalin, I. G., Handing, K. B., Minor, W. Albumin-based transport of nonsteroidal anti-inflammatory drugs in mammalian blood plasma. *Journal of Medicinal Chemistry*, 63, 2020, 6847-6862.
38. Ioele, G., Chieffallo, M., Occhiuzzi, M. A., De Luca, M., Garofalo, A., Ragno, G., et al. Anticancer drugs: Recent strategies to improve stability profile, pharmacokinetic, and pharmacodynamic properties. *Molecules*, 27, 2022, 5436.
39. Botti, G., Dalpiaz, A., & Pavan, B. Targeting systems to the brain obtained by merging prodrugs, nanoparticles, and nasal administration. *Pharmaceutics*, 13, 2021, 1144.
40. Liu, J., Wang, T., Dong, J., & Lu, Y. The blood-brain barrier: Novel nanocarriers for central nervous system diseases. *Journal of Nanobiotechnology*, 23, 2025.
41. Anwarkhan, S., Koilpillai, J., & Narayanasamy, D. Utilizing multifaceted approaches to target drug delivery in the brain: From nanoparticles to biological therapies. *Cureus*, 16, 2024.
42. Noga, M., & Jurowski, K. Toxicity of Bromo-DragonFLY as a new psychoactive substance: Application of in silico methods for the prediction of key toxicological parameters important to clinical and forensic toxicology. *Chemical Research in Toxicology*, 37, 2024, 1821-1842.
43. Adomako-Bonsu, A. G., Jacobsen, J., & Maser, E. Metabolic activation of 2,4,6-trinitrotoluene; a case for ROS-induced cell damage. *Redox Biology*, 72, 2024, 103082.
44. Escobar, P. A., Sobol, Z., Miller, R. R., Ferry-Martin, S., Stermer, A., Jacob, B., et al. Comprehensive genotoxicity and carcinogenicity assessment of molnupiravir. *Toxicological Sciences*, 2024, 202, 278-290.
45. Jaladanki, C. K., Gahlawat, A., Rathod, G., Sandhu, H., Jahan, K., Bharatam, P. V. Mechanistic studies on the drug metabolism and toxicity originating from cytochromes P450. *Drug Metabolism Reviews*, 52, 2020, 366-394.
46. Roje, B., Zhang, B., Mastroilli, E., Kovačić, A., Sušak, L., Ljubenkova, I., et al. Gut microbiota carcinogen metabolism causes distal tissue tumors. *Nature*, 632, 2024, 1137-1144.

47. Santos, L. G. A., Jaiswal, S., Chen, K. F., Jones, H. M., Templeton, I. E. Real-world application of physiologically based pharmacokinetic models in drug discovery. *Drug Metabolism and Disposition*, 53, 2025, 100015.
48. Ozbek, O., Genc, D. E., & Ulgen, K. Advances in physiologically based pharmacokinetic (PBPK) modeling of nanomaterials. *ACS Pharmacology & Translational Science*, 7, 2024, 2251-2279.
49. Bettonte, S., Berton, M., Stader, F., Battegay, M., Marzolini, C. Development of a physiologically-based pharmacokinetic model to simulate the pharmacokinetics of intramuscular antiretroviral drugs. *CPT: Pharmacometrics & Systems Pharmacology*, 13, 2024, 781-794.
50. Hillisch, A., Schulz, S., Tersteegen, A., Schaefer, M., Heitmeier, S., Puetter, V., et al. Design, synthesis, and pharmacological characterization of a neutral, non-prodrug thrombin inhibitor with good oral pharmacokinetics. *Journal of Medicinal Chemistry*, 63, 2020, 12574-12594.
51. Kurzrock, R., Hobbs, B. P., Hong, D. S., Wu, T. C., Lin, C. C., & Pestana, R. C. Moving beyond 3+3: The future of clinical trial design. *American Society of Clinical Oncology Educational Book*, 41, 2021, e133-e144.
52. Paliwal, A., Anwer, K., Khandai, M., Gulati, M., Wal, P., Khandige, P. S., et al. Predictive modeling in pharmacokinetics: From in-silico simulations to personalized medicine. *Expert Opinion on Drug Metabolism & Toxicology*, 20, 2024, 181-195.
53. Imtiaz, S., Ferdous, U. T., Nizela, A., Hasan, A., Shakoor, A., Zia, A. W., et al. Mechanistic study of cancer drug delivery: Current techniques, limitations, and future prospects. *European Journal of Medicinal Chemistry*, 290, 2025, 117535.
54. Albayati, N., Talluri, S. R., Dholaria, N., & Michniak-Kohn, B. AI-driven innovation in skin kinetics for transdermal drug delivery: Overcoming barriers and enhancing precision. *Pharmaceutics*, 17, 2025, 188.
55. Simhadri, A., Sana, J., & Dommeti, M. A comprehensive review on the nanotechnology-based intranasal drug delivery systems for brain targeting. *Journal of Pharmaceutical and Industrial Research*, 2, 2024, 015-023.
56. Mukherjee, D., & Raikwar, S. Recent update on nanocarrier(s) as the targeted therapy for breast cancer. *AAPS PharmSciTech*, 25, 2024.
57. Abbasi, M., Boka, D. A., & Deloit, H. Nanomaterial-enhanced microneedles: Emerging therapies for diabetes and obesity. *Pharmaceutics*, 16, 2024, 1344.
58. Anwar, D. M., Hedeya, H. Y., Ghozlan, S. H., Ewas, B. M., Khattab, S. N. Surface-modified lipid-based nanocarriers as a pivotal delivery approach for cancer therapy: Application and recent advances in targeted cancer treatment. *Beni-Suef University Journal of Basic and Applied Sciences*, 13, 2024.
59. Kim, M., Shin, M., Zhao, Y., Ghosh, M., & Son, Y.-O. Transformative impact of nanocarrier-mediated drug delivery: Overcoming biological barriers and expanding therapeutic horizons. *Small Science*, 4, 2024.
60. Martin, H., Lázaro, L. R., Gunnlaugsson, T., & Scanlan, E. M. Glycosidase activated prodrugs for targeted cancer therapy. *Chemical Society Reviews*, 51, 2022, 9694-9716.
61. Wang, Q., Jin, D., Liu, C., Shi, L., & Li, T. A tumor-specific cascade-activating smart prodrug system for enhanced targeted therapy. *Small*, 20, 2023.
62. Kant, S., Deepika, D., & Roy, S. Artificial intelligence in drug discovery and development: Transforming challenges into opportunities. *Discovery Pharmaceutical Sciences*, 1, 2025.
63. Fu, C., & Chen, Q. The future of pharmaceuticals: Artificial intelligence in drug discovery and development. *Journal of Pharmaceutical Analysis*, 15, 2025, 101248.
64. Gupta, D., Wal, P., Wal, A., Sribhavani, K. R., Kumar, M., Panda, K. C., et al. AI in clinical trials and drug development: Challenges and potential advancements. *Current Drug Development and Therapeutics*, 22, 2025.
65. Mottaghi-Dastjerdi, N., & Soltany-Rezaee-Rad, M. Advancements and applications of artificial intelligence in pharmaceutical sciences: A comprehensive review. *Iranian Journal of Pharmaceutical Research*, 23, 2024.
66. Suriyaamporn, P., Pamornpathomkul, B., Patrojanasophon, P., Ngawhirunpat, T., Rojanarata, T., Opanasopit, P. The artificial intelligence-powered new era in pharmaceutical research and development: A review. *AAPS PharmSciTech*, 25, 2024.
67. Ali, K. A., Mohin, S., Mondal, P., Goswami, S., Ghosh, S., & Choudhuri, S. Influence of artificial intelligence in modern pharmaceutical formulation and drug development. *Future Journal of Pharmaceutical Sciences*, 10, 2024.